Search results
Results from the WOW.Com Content Network
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [ 8 ] [ 9 ] Epoetin alfa is an erythropoiesis-stimulating agent. [ 8 ]
n/a n/a Ensembl n/a n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) n/a n/a PubMed search n/a n/a Wikidata View/Edit Human Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n, - r ə -, - p ɔɪ ˈ ɛ t ɪ n, - ˈ iː t ɪ n / ; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys ...
The 2020 Cochrane Anaesthesia Review Group review of erythropoietin (EPO) plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non‐cardiac surgery [11] demonstrated that patients were much less likely to require red cell transfusion and in those transfused, the volumes were unchanged (mean ...
In response to these advisories, the FDA released a Public Health Advisory [14] on 9 March 2007, and a clinical alert [15] for doctors on 16 February 2007, about the use of erythropoeisis-stimulating agents (ESAs) such as epoetin alfa (marketed as Epogen) and darbepoetin alfa. The advisory recommended caution in using these agents in cancer ...
Epoetin beta (), sold under the brand name Neorecormon among others, is a synthetic, recombinant [4] form of erythropoietin, a protein that promotes the production of red blood cells.
Methoxy polyethylene glycol-epoetin beta, sold under the brand name Mircera, is a long-acting erythropoietin receptor activator (CERA) used for the treatment of anaemia associated with chronic kidney disease. [4]
Ozempic Dosing Chart and Schedule If you're taking Ozempic, you won't immediately start on the maximum 2.0 mg weekly dose. Instead, your healthcare provider will begin with 0.25 mg once-weekly doses.
In 1983 his team successfully established the gene coding for it [2] and recombinant human erythropoietin was approved by the US FDA in June 1989 [3] with the generic name epoetin alpha, tradename Epogen. [4] [5] Lin was also engaged in developing novel pharmaceutics and studying their molecular mechanisms.